Hippo-TAZ信号通路在乳腺癌及乳腺癌干细胞中的作用

doi:10.3760/cma.j.issn.1673-422X.2016.10.014

摘要/Abstract

摘要： Hippo信号通路在调节器官生长、组织再生、肿瘤发生、发展中起重要作用，而含有PDZ结合模序转录共激活因子（TAZ）是其下游核心转录因子，参与整个信号通路的调控。近年来，研究者发现TAZ过表达与乳腺癌的发生、发展、预后都有着密切的关系。探讨Hippo信号通路中TAZ与乳腺癌及乳腺癌干细胞的关系，可为乳腺癌诊断和治疗提供新的思路。

关键词: 乳腺肿瘤, 肿瘤干细胞, Hippo信号通路, 含有PDZ结合模序转录共激活因子

Abstract: Hippo signaling pathway plays an important role in the regulation of organ growth, tissue regeneration, tumor occurrence and development. Transcriptional coactivator with PDZbinding motif (TAZ) is the downstream transcription factor of Hippo signaling, participates in the regulation of the entire signaling pathway. In recent years, many studies have found that overexpression of TAZ has a close relationship with the occurrence, development and prognosis of breast cancer. Discussing the relationship of HippoTAZ with breast cancer and breast cancer stem cells may provide a new way for breast cancer diagnosis and treatment.

Key words: Breast neoplasms, Neoplastic stem cells, Hippo signaling, Transcriptional coactivator with PDZbinding motif

闫冰,卢颖,张春影,李青,毛俊,李连宏. Hippo-TAZ信号通路在乳腺癌及乳腺癌干细胞中的作用[J]. 国际肿瘤学杂志, 2016, 43(10): 779-782.

Yan Bing, Lu Ying, Zhang Chunying, Li Qing, Mao Jun, Li Lianhong. Roles of Hippo-TAZ signaling pathway in breast cancer and breast cancer stem cells[J]. Journal of International Oncology, 2016, 43(10): 779-782.

参考文献

［1］ Harvey KF, Zhang X, Thomas DM. The hippo pathway and human cancer［J］. Nat Rev Cancer, 2013, 13(4): 246-257. DOI: 10.1038/nrc3458. ［2］ Pan D. The hippo signaling pathway in development and cancer［J］. Dev Cell, 2010, 19(4): 491-505. DOI: 10.1016/j.devcel.2010.09.011. ［3］ Xiao H, Jiang N, Zhou B, et al. TAZ regulates cell proliferation and epithelialmesenchymal transition of human hepatocellular carcinoma［J］. Cancer Sci, 2015, 106(2): 151-159. DOI: 10.1111/cas.12587. ［4］ Xie D, Cui J, Xia T, et al. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression［J］. Oncotarget, 2015, 6(34): 35949-35963. DOI: 10.18632/oncotarget.5772. ［5］ RomeroPérez L, GarciaSanz P, Mota A, et al. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer［J］. Mod Pathol, 2015, 28(11): 1492-1503. DOI: 10.1038/modpathol.2015.102. ［6］ Cordenonsi M, Zanconato F, Azzolin L, et al. The hippo transducer TAZ confers cancer stem cellrelated traits on breast cancer cells［J］. Cell, 2011, 147(4): 759-772. DOI: 10.1016/j.cell.2011.09.048. ［7］ Azzolin L, Zanconato F, Bresolin S, et al. Role of TAZ as mediator of Wnt signaling［J］. Cell, 2012, 151(7): 1443-1456. DOI: 10.1016/j.cell.2012.11.027. ［8］ Lai D, Ho KC, Hao Y, et al. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF［J］. Cancer Res, 2011, 71(7): 2728-2738. DOI: 10.1158/00085472.CAN102711. ［9］ Zhao D, Zhi X, Zhou Z, et al. TAZ antagonizes the WWP1mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis［J］. Carcinogenesis, 2012, 33(1): 59-67. DOI: 10.1093/carcin/bgr242. ［10］ Chan SW, Lim CJ, Chen L, et al. The Hippo pathway in biological control and cancer development［J］. J Cell Physiol, 2011, 226(4): 928-939. DOI: 10.1002/jcp.22435. ［11］ Diepenbruck M, Waldmeier L, Ivanek R, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelialmesenchymal transition［J］. J Cell Sci, 2014, 127(Pt 7): 1523-1536. DOI: 10.1242/jcs.139865. ［12］ Varelas X, SamavarchiTehrani P, Narimatsu M, et al. The crumbs complex couples cell density sensing to hippodependent control of the TGFβSMAD pathway［J］. Dev Cell, 2010, 19(6): 831-844. DOI: 10.1016/j.devcel.2010.11.012. ［13］ Wang Y, Zhou BP. Epithelialmesenchymal transition in breast cancer progression and metastasis［J］. Chin J Cancer, 2011, 30(9): 603-611. DOI: 10.5732/cjc.011.10226. ［14］ Huang W, Lv X, Liu C, et al. The Nterminal phosphodegron targets TAZ/WWTR1 protein for SCFβTrCPdependent degradation in response to phosphatidylinositol 3kinase inhibition［J］. J Biol Chem, 2012, 287(31): 26245-26253. DOI: 10.1074/jbc.M112.382036. ［15］ Bartucci M, Dattilo R, Moriconi C, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells［J］. Oncogene, 2015, 34(6): 681-690. DOI: 10.1038/onc.2014.5. ［16］ Mi W, Lin Q, Childress C, et al. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration［J］. Oncogene, 2015, 34(24): 3095-3106. DOI: 10.1038/onc.2014.251. ［17］ Piccolo S, Cordenonsi M, Dupont S. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis［J］. Clin Cancer Res, 2013, 19(18): 4925-4930. DOI: 10.1158/10780432.CCR123172. ［18］ Zanconato F, Forcato M, Battilana G, et al. Genomewide association between YAP/TAZ/TEAD and AP1 at enhancers drives oncogenic growth［J］. Nat Cell Biol, 2015, 17(9): 1218-1227. DOI: 10.1038/ncb3216. ［19］ Yang N, Morrison CD, Liu P, et al. TAZ induces growth factorindependent proliferation through activation of EGFR ligand amphiregulin［J］. Cell Cycle, 2012, 11(15): 2922-2930. DOI: 10.4161/cc.21386. ［20］ Ehmer U, Sage J. Control of proliferation and cancer growth by the Hippo signaling pathway［J］. Mol Cancer Res, 2016， 14（2）：127-140. DOI: 10.1158/15417786.MCR150305. ［21］ Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor βinduced tumorigenic phenotypes in breast cancer cells［J］. J Biol Chem, 2014, 289(19): 13461-13474. DOI: 10.1074/jbc.M113.529115. ［22］ Keller PJ, Arendt LM, Skibinski A, et al. Defining the cellular precursors to human breast cancer［J］. Proc Natl Acad Sci USA, 2012, 109(8): 2772-2777. DOI: 10.1073/pnas.1017626108. ［23］ Lu Y, Ma W, Mao J, et al. Salinomycin exerts anticancer effects on human breast carcinoma MCF7 cancer stem cells via modulation of Hedgehog signaling［J］. Chem Biol Interact, 2015, 228(228): 100-107. DOI: 10.1016/j.cbi.2014.12.002. ［24］ Lai D, VisserGrieve S, Yang X. Tumour suppressor genes in chemotherapeutic drug response［J］. Biosci Rep, 2012, 32(4): 361-374. DOI: 10.1042/BSR20110125. ［25］ Chang C, Goel HL, Gao H, et al. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells［J］. Genes Dev, 2015, 29(1): 1-6. DOI: 10.1101/gad.253682.114. ［26］ Luo M, Brooks M, Wicha MS. Epithelialmesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance［J］. Curr Pharm Des, 2015, 21(10): 1301-1310. ［27］ Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway［J］. Nat Cell Biol, 2014, 16(4): 357-366. DOI: 10.1038/ncb2936. ［28］ Fernández BG, Gaspar P, BrásPereira C, et al. ActinCapping protein and the hippo pathway regulate factin and tissue growth in drosophila［J］. Development, 2011, 138(11): 2337-2346. DOI: 10.1242/dev.063545. ［29］ Thomasy SM, Morgan JT, Wood JA, et al. Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells［J］. Exp Eye Res, 2013, 113: 66-73. DOI: 10.1016/j.exer.2013.05.014.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.